Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.90
+0.09 (0.92%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 23, with a low estimate of 18 and a high estimate of 26. The average target predicts an increase of 132.32% from the current stock price of 9.90.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 16, 2026.
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +132.32% | Mar 16, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +142.42% | Nov 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $29 → $24 | Buy | Maintains | $29 → $24 | +142.42% | Nov 6, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +81.82% | Aug 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +192.93% | Jul 10, 2025 |
Financial Forecast
Revenue This Year
146.15M
from 106.47M
Increased by 37.27%
Revenue Next Year
224.22M
from 146.15M
Increased by 53.42%
EPS This Year
0.50
from 1.35
Decreased by -63.27%
EPS Next Year
1.52
from 0.50
Increased by 205.71%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 176.4M | 354.4M | ||||||
| Avg | 146.2M | 224.2M | ||||||
| Low | 131.9M | 174.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 65.7% | 142.5% | ||||||
| Avg | 37.3% | 53.4% | ||||||
| Low | 23.9% | 19.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.07 | 3.37 | ||||||
| Avg | 0.50 | 1.52 | ||||||
| Low | 0.15 | 0.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -20.7% | 579.8% | ||||||
| Avg | -63.3% | 205.7% | ||||||
| Low | -88.7% | 23.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.